What is USANA Health Sciences's hiya — cost of sales?

USANA Health Sciences (USNA) reported hiya — cost of sales of $9.98M in Q1 2026.

How has USANA Health Sciences's hiya — cost of sales changed year-over-year?

USANA Health Sciences's hiya — cost of sales decreased by 29.2% year-over-year, from $14.11M to $9.98M.

What does hiya — cost of sales mean?

Includes the direct costs attributable to the production and distribution of goods or services sold within the Hiya segment. This encompasses raw materials, direct labor, and manufacturing overheads directly associated with the segment's revenue generation. Monitoring this metric is critical for assessing the segment's gross margin and production efficiency.

USANA Health Sciences (USNA) Hiya — Cost of Sales

Screener

Other segment segments

Core Nutritional

$36.75M—

Rise

$12.7M—

Similar metrics at other companies

BROSLabor costs — Cost of Sales

$129.46M+27.8%

TGTMerchandising Cost of Sales — Cost of Sales

$16.28B+6.0%

BROSOccupancy & other costs — Cost of Sales

$83.09M+38.5%

BROSPre-opening costs — Cost of Sales

$8.41M+85.1%

CHEFFood Processing Costs — Cost of Sales

$15.45M-6.5%

SOLVCost of product — Cost of Sales

$807M-6.7%

Other financials

Income statement

See full

Revenue$250.2M+0.3%

Gross profit$190.8M-3.2%

Operating income$13.9M-11.5%

Net income$7.5M-20.1%

EPS (diluted)$0.41-16.3%

Balance sheet

See full

Cash & equivalents$165.7M-9.2%

Total debt$18.0M+10.8%

Total equity$543.6M+2.6%

Total assets$739.0M-1.0%

Cash flow

See full

Operating cash flow$9.8M-37.0%

CapEx$2.6M-5.6%

Free cash flow$7.1M-43.9%

Valuation

See full

Market cap$264.76M-50.6%

P/E13.2×+5.7×

P/S0.3×-0.3×

Profitability

See full

Gross margin77.6%-3.0pp

Operating margin3.8%-2.7pp

Net margin1.9%-4.4pp

FCF margin5.7%-1.1pp

Returns & leverage

See full

Return on equity3.2%-7.6pp

Debt / equity0×0.0×

Current ratio2.5×+0.5×

Where this comes from

Reported directly by USANA Health Sciences in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: USANA Health Sciences’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 4:35 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q2 2026
Accession: 0000896264-26-000034

Line item	Core Nutritional	Hiya	Rise	Total
Net sales (1)	$204,399	$32,150	$13,669	$250,218
Less:
Cost of sales	36,749	9,983	12,704	59,436
Brand Partner incentives	88,654	—	—	88,654
Selling, general and administrative (2)	60,747	24,771	2,736	88,254
Segment earnings (loss) from operations	$18,249	$(2,604)	$(1,771)	$13,874
Reconciliation of segment earnings from operations
Interest income				437

Item 1. FINANCIAL STATEMENTS

FAQ

What is USANA Health Sciences's hiya — cost of sales?: USANA Health Sciences (USNA) reported hiya — cost of sales of $9.98M in Q1 2026.
How has USANA Health Sciences's hiya — cost of sales changed year-over-year?: USANA Health Sciences's hiya — cost of sales decreased by 29.2% year-over-year, from $14.11M to $9.98M.
What does hiya — cost of sales mean?: Includes the direct costs attributable to the production and distribution of goods or services sold within the Hiya segment. This encompasses raw materials, direct labor, and manufacturing overheads directly associated with the segment's revenue generation. Monitoring this metric is critical for assessing the segment's gross margin and production efficiency.